The US Food and Drug Administration (FDA) has recently approved Medtronic’s state-of-the art Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application, which followed closely on the recent achievement of CE Mark in March.
The ActivaProgramming Application has been designed with the input of over a hundred clinicians from around the world and is managed on the Samsung Galaxy Tab S2 tablet interface. This modern, familiar tool will enhance the clinical programming experience, streamline workflows and provide actionable information to support neurologists and neurosurgeons in their treatment of patients that use the market leading, Medtronic Activa DBS system as therapy for neurological diseases such as Parkinson’s disease and Dystonia.
The programmer will also enable the upgrade of Activa rechargeable implantable neurostimulators service life to 15 years, giving patients an additional six years until their next device replacement.
“After using the Medtronic Clinician Programmer for the first time, I am impressed with the thoughtfulness put into the user interface,” said Mohammad Maarouf, associate professor, head of the Department of Stereotaxy and Functional Neurosurgery, Cologne Merheim Medical Center, University of Witten/Herdecke, Germany. “Its intuitive, visual interface and task-based workflow makes daily use easier, saving me time to focus on what’s most important-my patients.”
The Medtronic DBS Clinician Programmer is also approved for use with Medtronic Activa DBS systems that treat medically refractory epilepsy, a therapy that will be launched later this year in the US.
The European launch of the Medtronic DBS Clinician Programmer is underway, with the US launch expected to take place before the end of July 2018.
